Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 2.53
NAS:ALDR's Cash-to-Debt is ranked lower than
74% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. NAS:ALDR: 2.53 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ALDR' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.75  Med: No Debt Max: No Debt
Current: 2.53
1.75
No Debt
Debt-to-Equity 0.63
NAS:ALDR's Debt-to-Equity is ranked lower than
68% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. NAS:ALDR: 0.63 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:ALDR' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.52  Med: 0.57 Max: 0.63
Current: 0.63
0.52
0.63
Debt-to-EBITDA -0.70
NAS:ALDR's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. NAS:ALDR: -0.70 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:ALDR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.7  Med: 0 Max: 0
Current: -0.7
-0.7
0
Piotroski F-Score: 3
Altman Z-Score: -0.92
WACC vs ROIC
26.25%
-363.01%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -28231.41
NAS:ALDR's Operating Margin % is ranked lower than
95% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. NAS:ALDR: -28231.41 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ALDR' s Operating Margin % Range Over the Past 10 Years
Min: -140626.55  Med: -110.45 Max: 16.09
Current: -28231.41
-140626.55
16.09
Net Margin % -28920.62
NAS:ALDR's Net Margin % is ranked lower than
95% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. NAS:ALDR: -28920.62 )
Ranked among companies with meaningful Net Margin % only.
NAS:ALDR' s Net Margin % Range Over the Past 10 Years
Min: -138277.88  Med: -109.67 Max: 16.28
Current: -28920.62
-138277.88
16.28
ROE % -99.31
NAS:ALDR's ROE % is ranked lower than
75% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. NAS:ALDR: -99.31 )
Ranked among companies with meaningful ROE % only.
NAS:ALDR' s ROE % Range Over the Past 10 Years
Min: -99.31  Med: -40.57 Max: -38.27
Current: -99.31
-99.31
-38.27
ROA % -58.49
NAS:ALDR's ROA % is ranked lower than
72% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. NAS:ALDR: -58.49 )
Ranked among companies with meaningful ROA % only.
NAS:ALDR' s ROA % Range Over the Past 10 Years
Min: -81.11  Med: -37.72 Max: 19.56
Current: -58.49
-81.11
19.56
ROC (Joel Greenblatt) % -4778.36
NAS:ALDR's ROC (Joel Greenblatt) % is ranked lower than
77% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. NAS:ALDR: -4778.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ALDR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4778.36  Med: -1191.61 Max: 750.46
Current: -4778.36
-4778.36
750.46
3-Year Revenue Growth Rate -75.30
NAS:ALDR's 3-Year Revenue Growth Rate is ranked lower than
88% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NAS:ALDR: -75.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ALDR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -100  Med: -95.3 Max: -75.3
Current: -75.3
-100
-75.3
GuruFocus has detected 3 Warning Signs with Alder BioPharmaceuticals Inc NAS:ALDR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ALDR's 30-Y Financials

Financials (Next Earnings Date: 2019-02-23 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2017

ALDR Guru Trades in Q4 2017

Steven Cohen Sold Out
Paul Tudor Jones Sold Out
» More
Q1 2018

ALDR Guru Trades in Q1 2018

Jim Simons 322,300 sh (New)
Louis Moore Bacon 100,000 sh (New)
Leon Cooperman 189,500 sh (New)
» More
Q2 2018

ALDR Guru Trades in Q2 2018

Steven Cohen 123,800 sh (New)
Paul Tudor Jones 12,013 sh (New)
Pioneer Investments 123,900 sh (New)
Jim Simons 434,800 sh (+34.91%)
Louis Moore Bacon Sold Out
Leon Cooperman Sold Out
» More
Q3 2018

ALDR Guru Trades in Q3 2018

Paul Tudor Jones 34,717 sh (+189.00%)
Steven Cohen 29,100 sh (unchged)
Pioneer Investments Sold Out
Steven Cohen Sold Out
Jim Simons 101,500 sh (-76.66%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ALDR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:VNDA, SZSE:300363, NAS:MNLO, NAS:DOVA, NAS:JNCE, TSE:2931, XSWX:BSLN, BOM:540701, TPE:6541, TSX:PLI, NAS:QURE, XKRX:096530, NAS:ANIK, OSTO:RECI B, ROCO:4105, SZSE:300497, NAS:CERS, NAS:CBAY, NAS:ECYT, ROCO:4162 » details
Traded in other countries:3A9.Germany,
Headquarter Location:USA
Alder BioPharmaceuticals Inc is a biotechnology company. It is engaged in the discovery, development, and commercialization of therapeutic antibodies addresses diseases with limited medical options. The company operates across the U.S and Australia.

Alder BioPharmaceuticals is a biotechnology company that seeks to discover, develop, and commercialize therapeutic antibodies. The company's antibody platform seeks to maximize efficacy, as well as speed of onset and durability of therapeutic response. Alder's product pipeline addresses diseases where patients have limited medical options or where current medical options may not meet the needs of a substantial number of patients. The company operates in two geographic regions: the United States and Australia. The vast majority of the Alder's assets are located in the United States, where the vast majority of its revenue is also generated.

Ratios

vs
industry
vs
history
PB Ratio 4.27
ALDR's PB Ratio is ranked lower than
60% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. ALDR: 4.27 )
Ranked among companies with meaningful PB Ratio only.
ALDR' s PB Ratio Range Over the Past 10 Years
Min: 1.82  Med: 3.71 Max: 17.46
Current: 4.27
1.82
17.46
PS Ratio 821.43
ALDR's PS Ratio is ranked lower than
97% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALDR: 821.43 )
Ranked among companies with meaningful PS Ratio only.
ALDR' s PS Ratio Range Over the Past 10 Years
Min: 1.47  Med: 505.36 Max: 16985
Current: 821.43
1.47
16985
EV-to-EBIT -2.37
ALDR's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. ALDR: -2.37 )
Ranked among companies with meaningful EV-to-EBIT only.
ALDR' s EV-to-EBIT Range Over the Past 10 Years
Min: -3297.7  Med: -4.6 Max: 102.2
Current: -2.37
-3297.7
102.2
EV-to-EBITDA -2.40
ALDR's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. ALDR: -2.40 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALDR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -150.4  Med: -4.2 Max: 4433.3
Current: -2.4
-150.4
4433.3
EV-to-Revenue 655.44
ALDR's EV-to-Revenue is ranked lower than
94% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. ALDR: 655.44 )
Ranked among companies with meaningful EV-to-Revenue only.
ALDR' s EV-to-Revenue Range Over the Past 10 Years
Min: 5.5  Med: 430.6 Max: 11529.4
Current: 655.44
5.5
11529.4
Current Ratio 15.34
ALDR's Current Ratio is ranked higher than
78% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. ALDR: 15.34 )
Ranked among companies with meaningful Current Ratio only.
ALDR' s Current Ratio Range Over the Past 10 Years
Min: 0.63  Med: 12.29 Max: 65.84
Current: 15.34
0.63
65.84
Quick Ratio 15.34
ALDR's Quick Ratio is ranked higher than
79% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. ALDR: 15.34 )
Ranked among companies with meaningful Quick Ratio only.
ALDR' s Quick Ratio Range Over the Past 10 Years
Min: 0.63  Med: 12.29 Max: 65.84
Current: 15.34
0.63
65.84
Days Inventory 146.00
ALDR's Days Inventory is ranked lower than
51% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. ALDR: 146.00 )
Ranked among companies with meaningful Days Inventory only.
ALDR' s Days Inventory Range Over the Past 10 Years
Min: 105.51  Med: 808.6 Max: 1511.68
Current: 146
105.51
1511.68
Days Payable 6.00
ALDR's Days Payable is ranked lower than
93% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. ALDR: 6.00 )
Ranked among companies with meaningful Days Payable only.
ALDR' s Days Payable Range Over the Past 10 Years
Min: 6  Med: 17575.64 Max: 33466.95
Current: 6
6
33466.95

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -29.80
ALDR's 3-Year Average Share Buyback Ratio is ranked lower than
74% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. ALDR: -29.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALDR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -269.1  Med: -252 Max: -29.8
Current: -29.8
-269.1
-29.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.26
ALDR's Price-to-Net-Cash is ranked lower than
68% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. ALDR: 3.26 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ALDR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.66  Med: 4.81 Max: 25.4
Current: 3.26
2.66
25.4
Price-to-Net-Current-Asset-Value 5.11
ALDR's Price-to-Net-Current-Asset-Value is ranked lower than
97% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. ALDR: 5.11 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ALDR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.5  Med: 4.66 Max: 87.78
Current: 5.11
2.5
87.78
Price-to-Tangible-Book 4.27
ALDR's Price-to-Tangible-Book is ranked lower than
51% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. ALDR: 4.27 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ALDR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.37  Med: 3.69 Max: 17.23
Current: 4.27
2.37
17.23
Price-to-Median-PS-Value 1.62
ALDR's Price-to-Median-PS-Value is ranked lower than
90% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. ALDR: 1.62 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALDR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.03  Med: 1.62 Max: 32.45
Current: 1.62
0.03
32.45
Earnings Yield (Greenblatt) % -42.19
ALDR's Earnings Yield (Greenblatt) % is ranked lower than
71% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. ALDR: -42.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALDR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -118.8  Med: -14.4 Max: 4.1
Current: -42.19
-118.8
4.1

More Statistics

Revenue (TTM) (Mil) $0.94
EPS (TTM) $ -4.38
Beta3.90
Volatility51.10%
52-Week Range $10.45 - 20.87
Shares Outstanding (Mil)68.33

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 5 38 169
EBIT (Mil $) -267 -235 -210
EBITDA (Mil $) -269 -220 -195 -37
EPS ($) -4.63 -3.44 -2.62 -0.63
EPS without NRI ($) -4.63 -3.44 -2.62 -0.63
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}